Tango Therapeutics Inc.
TNGXHeld by 16 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying16 funds opened new positions. Next phase2 readout (TNG260): Jan 2026. Short interest: 25.9% of float.
Held by 16 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying16 funds opened new positions. Next phase2 readout (TNG260): Jan 2026. Short interest: 25.9% of float.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.